Conjuran Polynucleotide Osteoarthritis of The Knee Joint. Reduce Cartilage Friction

• Customization: Available
• CAS No.: 100403-24-5
• Formula: C39h51n15o25p4
• Model NO.: Conjuran
• EINECS: 309-566-6
• Environmental Protection: Yes
• Certification: ISO9001,Kgmp
• Color: White
• Classification: Polynucleotide
• Function: Knee Osteoarthritis
• Appearance: Liquid
• Transport Package: 5syr/Box
• Specification: 2ml/syr
• Trademark: Conjuran
• Origin: Korea
• Production Capacity: 5000boxes/Month

Product Description

Conjuran Polynucleotide Osteoarthritis of the knee joint  

Ingredients: Sodium Polynucleotide 20mg/mL
Purpose of use: It is used to reduce mechanical friction in the joint area through physical restoration by injecting it into the joint cavity.
Target patients: Radiologically low-grade (KL grade I, II, III) osteoarthritis of the knee joint
Administration period · Frequency:  up to 5 administrations within 6 months  * Same as sodium hyaluronate drug formulation · Simultaneous administration prohibited
Weight or packaging unit: 2mL X 5syrs / Box 
Storage method: room temperature (1~30°C)
 

Ingredients	Sodium Polynucleotide 20mg/ml
Specification	2ml*5sys/box
Function	Knee osteoarthritis

 
Description:
"Conjuran (CONJURAN) will be a new therapeutic alternative for arthritis patients, and we expect high sales in a short period of time without much competition and this New Health Technology is currently available as a non-reimbursement for the patient at the hospital, and we will submit an application for medical care benefits to the Health Insurance Review & Assessment Service." said a PharmaResearch Products official.

PharmaResearch Products' 'Conjuran (CONJURAN)' was approved by the Ministry of Food and Drug Safety in October 2017, and has since been classified and evaluated by the National Evidence based Healthcare Collaborating Agency (NECA) as a subject of New Health Technology Assessment.
 
In particular, using sodium polynucleotide has proven to be a valid technique for improving pain and joint function in patients with knee osteoarthritis compared to the existing technique using sodium hyaluronate or steroid injection. In terms of safety, the treatment material has been evaluated as a safe technology with no side effects so far.
 
Sodium polynucletide, the raw material of 'Conjuran (CONJURAN)', which is listed as New Health Technology, is a safe DNA substance extracted from reproductive cells of salmon and fish, not only does it undergo high purification process to be suitable for injecting into human tissues such as joint, but also it is manufactured by the company's patented DOT (DNA Optimization Technology) Technology to maximize the performance of the product.
 
The main component of Conjuran, sodium polynucleotide, has the properties that binds to large amounts of water molecules, resulting in the form of gel, which exhibits high viscosity and elasticity. In fact, 'Conjuran (CONJURAN)' is injected into damaged joints to act as a buffer and lubricant, and clinical results also showed that the patient's knee pain and function evaluation scores after the procedure were more than equivalent to sodium hyaluronic acid, a conventional intra-articular injection.
 
Until now, the method of injecting steroids and sodium hyaluronic acid into the space of the joint (articular cavity) has been used for a long time, but controversy has continued, with academic circles raising questions about continued use, respectively.
 
"Conjuran (CONJURAN) will be a new therapeutic alternative for arthritis patients, and we expect high sales in a short period of time without much competition and this New Health Technology is currently available as a non-reimbursement for the patient at the hospital, and we will submit an application for medical care benefits to the Health Insurance Review & Assessment Service." said a PharmaResearch Products official.
 
Meanwhile, the domestic osteoarthritis market is worth about 960 billion won (as of 2018), and 'Conjuran' is the first medical device to be approved for the disease and is expected to become an innovative treatment method to challenge the sodium hyaluronic acid intra-articualr injection which is performed more than 5 million times a year.

Effects of Conjuran®
As a result of clinical trials, the use of Conjuran® three times reduced the VAS* level of the knee joint.

*VAS Abbreviation for "visual analog scale", which refers to a visual analog scale. It is one of the pain scales as a method to evaluate the intensity of subjective pain, and records 'no pain' on the left side of the line and 'unbearable pain' on the right side of the line, and the patient indicates the pain level.